Insider trade

Director sold ~$3.6K of REGN shares in the open market

Traded May 1, 2026 · Filed May 4, 2026

~$3.6K
Reported value · 5 sh @ $711.49: 18K
Holds after · shares reported: +4.8%
stock since the trade · S&P 500 +6.0%, $701.42 → $734.81 on Oct 1

Why it stands out

A board member of Regeneron Pharmaceuticals sold $3.6K of Regeneron Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: May 1, 2026
Reporting period: Not applicable
Filed with the SEC: May 4, 2026

Director<$25KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$3,557

Shares × reported transaction price

Timing vs results

2 days after results of Apr 29, 2026, 66 days before results of Jul 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $701.42 on May 1, 2026, 45% above its 52-week low and 14% below its high, after a 5% drop over the previous 30 trading days

52-week range $483.07 (Jun 5, 2025) to $812.27 (Jan 7, 2026), 66% of the way up, from 251 adjusted closes. 30 trading days earlier: $737.45 on Mar 19, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved Dupixent on Apr 22, 2026, 9 days before this trade.

New use approved (efficacy supplement). Active ingredient: Dupilumab. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	+3.0%	+2.0%	+1.0%
30 days	-10.5%	+4.6%	-15.1%
90 days	+8.1%	+4.7%	+3.4%

Past results only. Not a forecast.

Source receipt

Record ID: 0001187443-26-000008
Filed / recorded: May 4, 2026, 8:14 PM UTC
Added to OQRO: Oct 2, 2026, 12:28 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: REGENERON PHARMACEUTICALS, INC.
Issuer CIK: 872589
Ticker: REGN
Reporting person: Arthur F Ryan
Relationship: Director
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: May 1, 2026
Transaction code: S
Shares / units: 5
Price per share: $711.49
Acquired / disposed: Disposed (D)
Shares owned after: 17,506
Ownership form: Direct
Amendment: No

Footnotes from the filing

Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on October 31, 2025.
Represents volume-weighted average price of sales of 5 shares of Company stock on May 1, 2026 at prices ranging from $711.17 to $711.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2026 at each separate price.

Around the same time

Director sold ~$3.5K of Regeneron Pharmaceuticals

Scheduled in advance5mo ago

Director sold ~$11K of Regeneron Pharmaceuticals

Scheduled in advance5mo ago

Director sold ~$17K of Regeneron Pharmaceuticals

Scheduled in advance5mo ago

Why it stands out

Dates, kept separate

Context

After it was reported

Source receipt

Footnotes from the filing

Around the same time

Most active this month